Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoString Technologies, a provider of life science tools for translational research and molecular diagnostic products, has secured an option to an exclusive worldwide license for a 186-gene signature from US-based The Broad Institute.
Subscribe to our email newsletter
The186-gene signature is used to determine the prognosis of patients diagnosed with liver cancer, hepatocellular carcinoma (HCC), or with hepatitis C-related early-stage cirrhosis.
During the period of exercising the option, NanoString has planned to assess the feasibility of developing an in vitro diagnostic assay based on the HCC gene signature for use on the nCounter Analysis System.
NanoString president and CEO Brad Gray said, "On the heels of launching our Prosigna breast cancer assay in the European Union and Israel, we are excited at the prospect of once again partnering with a customer of our Life Sciences business to translate their discovery into a diagnostic product."